Nephrology
Management of Diabetes Mellitus in patients with CKD: Core Curriculum 2022.
17 Oct, 2021 | 21:23h | UTC
Home Hemodialysis: Core Curriculum 2021.
14 Oct, 2021 | 09:55h | UTCHome Hemodialysis: Core Curriculum 2021 – American Journal of Kidney Diseases
Commentary on Twitter
Nephrologists and dialysis providers must embrace new technologies and improve their understanding of home hemodialysis systems. Review the benefits, pitfalls, and challenges of HHD in this Core Curriculum by @ScottDBieber and Bessie Young:https://t.co/TAPiH4wSIA (FREE) pic.twitter.com/dgeX0XKiuL
— AJKD (@AJKDonline) October 5, 2021
Consensus Guidance: Hyperkalemia management in the emergency department.
13 Oct, 2021 | 01:34h | UTCPodcast: Hyperkalemia, Diet, K+ Binders, Exercise
Hyperkalemia: Pathophysiology, Risk Factors and Consequence
Hyperkalemia: Pathophysiology, Risk Factors and Consequence (several articles)
Study suggests a 30-second interval between automated office blood pressure measurements is as accurate and reliable as a 60-second interval.
8 Oct, 2021 | 10:09h | UTCImpact of 30- Versus 60-Second Time Intervals Between Automated Office Blood Pressure Measurements on Measured Blood Pressure – Hypertension (link to abstract – $ for full-text)
Commentary on Twitter
Guidelines recommend a 60-sec pause between automated office BP measures. This study indicates a 30-sec interval not only saves time but is just as accurate and reliable. @spjuraschek @therealaishak @TimAndersonMD @jenniferlcluett https://t.co/A77bvhatZq pic.twitter.com/wdrUqZDWs4
— Hypertension (@HyperAHA) October 7, 2021
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice.
7 Oct, 2021 | 10:17h | UTC
Commentary on Twitter
The diagnostic yield of genome sequencing in patients with chronic kidney disease is about 30% in children and 15-20% in adults. Should it be performed in clinical practice? @knoers and coauthors provide an informative review and recommendations. https://t.co/Pzwl0ztTLU pic.twitter.com/tWbko9mOyK
— Muin J. Khoury (@MuinJKhoury) July 23, 2021
Long-Term Immunosuppression Management: Opportunities and Uncertainties.
7 Oct, 2021 | 10:15h | UTC
Commentary on Twitter
Long-Term Immunosuppression Management: Opportunities and Uncertainties. A Review evaluates the current state of maintenance immunosuppression in kidney transplant recipients and discusses areas of opportunity and uncertainty in their long-term use. https://t.co/8yWp4PVD7t
— CJASN (@CJASN) August 16, 2021
Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.
7 Oct, 2021 | 10:14h | UTC
Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.
6 Oct, 2021 | 09:57h | UTCNews release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine
Commentary on Twitter (thread – click for more)
Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v
— Jeremy Sussman (@JeremySussman) October 5, 2021
Is salt good for you after all? The evidence says no.
6 Oct, 2021 | 08:52h | UTCIs salt good for you after all? The evidence says no – The Conversation
Related:
Systematic Review: Altered dietary salt intake for people with chronic kidney disease.
New WHO benchmarks help countries reduce salt intake and save lives.
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels
Podcast: Urinary Stone Disease.
5 Oct, 2021 | 08:50h | UTC#298 Urinary Stone Disease Will Rock Your World – The Curbsiders
Review: Membranous nephropathy.
1 Oct, 2021 | 10:01h | UTCMembranous nephropathy – Nature Reviews Disease Primers (free for a limited period)
Infographic: Membranous nephropathy (free for a limited period)
Commentary on Twitter
Get Primed on Membranous #nephropathy with our NEW PrimeView, FREE to download this week!https://t.co/LVNEKceqC1 pic.twitter.com/mkAYnEbiM4
— Nature Reviews Disease Primers (@DiseasePrimers) September 30, 2021
Review: Monitoring of Treatment for Arterial Hypertension.
29 Sep, 2021 | 09:59h | UTCMonitoring of Treatment for Arterial Hypertension – Deutsches Ärzteblatt International
Expert panel recommends against use of race in assessment of kidney function.
24 Sep, 2021 | 09:01h | UTCExpert panel recommends against use of race in assessment of kidney function – STAT
Commentary on Twitter
A Unifying Approach for GFR Estimation: Recommendations of the @nkf – @ASNKidney Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease https://t.co/0qt8F7l9Wm (FREE)#KidneyDisease #HealthEquity pic.twitter.com/QVkMnsBA6B
— AJKD (@AJKDonline) September 23, 2021
Landmark articles suggest eliminating race in the estimation of kidney function.
24 Sep, 2021 | 09:03h | UTCStudy 2: Race, Genetic Ancestry, and Estimating Kidney Function in CKD – New England Journal of Medicine
Commentaries:
Remove Race From Equation Used to Assess Kidney Function, Researchers Say – AJMC
Commentary on Twitter
Honored to contribute to the NEW 2021 CKD-EPI #race-free #eGFR equation in our latest research published in @NEJM today. I learned a ton about equations. Importantly, the main lesson is that #race should NOT be incorporated into #biological tools. https://t.co/RvfWWwGOox pic.twitter.com/Xub23AUXht
— Amaka Eneanya, MD, MPH (@AmakaEMD) September 23, 2021
KDIGO 2021 clinical practice guideline for the management of glomerular diseases.
21 Sep, 2021 | 09:05h | UTCExecutive summary: KDIGO 2021 Guideline for the Management of Glomerular Diseases – Kidney Disease: Improving Global Outcomes
Systematic Review: Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
16 Sep, 2021 | 09:53h | UTC
Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study.
10 Sep, 2021 | 05:33h | UTCCovid-19: Infection increases the risk of kidney disease even in mild cases, finds study – The BMJ
Original study: Kidney Outcomes in Long COVID – Journal of the American Society of Nephrology
Long COVID and kidney disease.
10 Sep, 2021 | 05:31h | UTCLong COVID and kidney disease – Nature Reviews Nephrology
NICE Guideline: Assessment and management of chronic kidney disease.
1 Sep, 2021 | 09:47h | UTC
Study shows that current definitions of chronic kidney disease overestimate the CKD burden in older individuals and results in overdiagnosis.
1 Sep, 2021 | 09:43h | UTCAccounting for Age in the Definition of Chronic Kidney Disease – JAMA Internal Medicine (free for a limited period)
Invited commentary: Overdiagnosis of Chronic Kidney Disease in Older Adults—An Inconvenient Truth – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
Should the definition of chronic kidney disease be changed to consider the physiological eGFR decline that is associated with ageing?
A new publication says yes!
To learn more visit: https://t.co/BfVrSGQ9fv pic.twitter.com/3Dpd8MDJDr
— Chronic Disease Care (@ICDC_Research) August 31, 2021
#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.
29 Aug, 2021 | 19:21h | UTCEffect of Salt Substitution on Cardiovascular Events and Death – New England Journal of Medicine (link to abstract – $ for full-text)
News release: Low-sodium salt prevents stroke – European Society of Cardiology
Commentary: Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD – TCTMD
Commentary on Twitter
SSaSS: In RCT that compared salt substitute w/ regular salt, rates of stroke, major CV events, death lower with salt sub. #ESCCongress https://t.co/Yt6vMrYSDh pic.twitter.com/jtymS36zqs
— NEJM (@NEJM) August 29, 2021
#ESCCongress – RCT: Finerenone reduced CV events in patients with kidney disease and type 2 diabetes (12.4% vs. 14.2% during a median follow-up of 3.4 years), but the risk of hyperkalemia was increased (10.8% vs. 5.3%).
29 Aug, 2021 | 18:14h | UTCNews release: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology
Commentaries:
Related:
Commentary on Twitter
FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa
— NEJM (@NEJM) August 28, 2021
#ESCCongress – RCT: Initial hypertension treatment with a single pill with 4 drugs at quarter doses (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) achieved better BP lowering vs. standard monotherapy (irbesartan 150 mg).
29 Aug, 2021 | 18:11h | UTCInitial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: Quadruple UltrA-low-dose tReaTment for hypErTension – QUARTET – American College of Cardiology
New WHO Guideline for the pharmacological treatment of hypertension in adults.
26 Aug, 2021 | 08:57h | UTCGuideline for the pharmacological treatment of hypertension in adults – World Health Organization
Commentary on Twitter (thread – click for more)
The number of adults aged 30-79 living with #hypertension has doubled from 650 million to 1.28 billion since 1990, according to a 🆕 comprehensive global 🌎🌍🌏 analysis of trends in hypertension prevalence, detection, treatment and control.
👉 https://t.co/MI48CX2kEO pic.twitter.com/ARpS8uipeY
— World Health Organization (WHO) (@WHO) August 25, 2021
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
25 Aug, 2021 | 08:56h | UTCCommentary: Global and national high blood pressure burden and control – The Lancet (free registration required)
Commentary on Twitter
Our new analysis within #NCDRisC on the #worldwide #hypertension #prevalence in last 30 yrs published in @TheLancet. The number of people with HTN doubled from 1990 with 626 million🕴️♀️ and 652 million 🕴️ in 2019. Control rates were ⬇️10% in some countries!https://t.co/FdjusD38X3 pic.twitter.com/famYphfqC8
— Maciej Banach (@maciejbanach) August 25, 2021